Neurogene (NGNE) Competitors $16.70 -0.10 (-0.60%) Closing price 03/14/2025 04:00 PM EasternExtended Trading$16.66 -0.04 (-0.25%) As of 03/14/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NGNE vs. NTLA, ELVN, ETNB, REPL, OCUL, SYRE, COLL, EOLS, ZYME, and DAWNShould you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include Intellia Therapeutics (NTLA), Enliven Therapeutics (ELVN), 89bio (ETNB), Replimune Group (REPL), Ocular Therapeutix (OCUL), Spyre Therapeutics (SYRE), Collegium Pharmaceutical (COLL), Evolus (EOLS), Zymeworks (ZYME), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical products" industry. Neurogene vs. Intellia Therapeutics Enliven Therapeutics 89bio Replimune Group Ocular Therapeutix Spyre Therapeutics Collegium Pharmaceutical Evolus Zymeworks Day One Biopharmaceuticals Intellia Therapeutics (NASDAQ:NTLA) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership. Do analysts prefer NTLA or NGNE? Intellia Therapeutics presently has a consensus target price of $37.56, suggesting a potential upside of 310.89%. Neurogene has a consensus target price of $60.83, suggesting a potential upside of 264.27%. Given Intellia Therapeutics' higher probable upside, equities analysts clearly believe Intellia Therapeutics is more favorable than Neurogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 1 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.63Neurogene 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the MarketBeat Community believe in NTLA or NGNE? Intellia Therapeutics received 417 more outperform votes than Neurogene when rated by MarketBeat users. However, 100.00% of users gave Neurogene an outperform vote while only 68.90% of users gave Intellia Therapeutics an outperform vote. CompanyUnderperformOutperformIntellia TherapeuticsOutperform Votes44368.90% Underperform Votes20031.10% NeurogeneOutperform Votes26100.00% Underperform VotesNo Votes Does the media prefer NTLA or NGNE? In the previous week, Intellia Therapeutics had 25 more articles in the media than Neurogene. MarketBeat recorded 26 mentions for Intellia Therapeutics and 1 mentions for Neurogene. Neurogene's average media sentiment score of 1.87 beat Intellia Therapeutics' score of 0.16 indicating that Neurogene is being referred to more favorably in the news media. Company Overall Sentiment Intellia Therapeutics Neutral Neurogene Very Positive Which has more risk & volatility, NTLA or NGNE? Intellia Therapeutics has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Is NTLA or NGNE more profitable? Neurogene's return on equity of -32.81% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intellia TherapeuticsN/A -49.34% -40.27% Neurogene N/A -32.81%-27.96% Do institutionals & insiders have more ownership in NTLA or NGNE? 88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 3.2% of Intellia Therapeutics shares are held by company insiders. Comparatively, 9.9% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has stronger earnings and valuation, NTLA or NGNE? Neurogene has lower revenue, but higher earnings than Intellia Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$57.88M16.35-$481.19M-$5.25-1.74Neurogene$925K268.19-$36.32MN/AN/A SummaryNeurogene beats Intellia Therapeutics on 8 of the 15 factors compared between the two stocks. Remove Ads Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NGNE vs. The Competition Export to ExcelMetricNeurogenePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$248.08M$7.02B$5.67B$8.12BDividend YieldN/A2.76%4.40%4.10%P/E RatioN/A6.2923.9019.07Price / Sales268.19232.75395.6188.27Price / CashN/A65.6738.1134.64Price / Book1.156.596.834.29Net Income-$36.32M$142.18M$3.20B$247.56M7 Day Performance-3.36%-1.29%6.58%-0.84%1 Month Performance-9.34%-8.94%-0.31%-9.37%1 Year Performance-55.50%-5.83%13.04%4.01% Neurogene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NGNENeurogene2.0917 of 5 stars$16.70-0.6%$60.83+264.3%-55.5%$248.08M$925,000.000.0090Upcoming EarningsPositive NewsNTLAIntellia Therapeutics4.4492 of 5 stars$9.46-6.2%$42.12+345.1%-67.7%$963.80M$43.09M-1.74600ELVNEnliven Therapeutics2.3597 of 5 stars$19.65-5.7%$38.25+94.7%+73.3%$960.08MN/A-10.3450Earnings ReportInsider TradeNews CoverageGap UpETNB89bio2.8739 of 5 stars$8.90-3.6%$30.29+240.3%-37.4%$944.42MN/A-3.0640Analyst ForecastNews CoverageREPLReplimune Group3.852 of 5 stars$12.11-4.5%$19.43+60.5%+36.6%$932.50MN/A-3.94210Positive NewsOCULOcular Therapeutix3.4238 of 5 stars$5.93-17.0%$17.00+186.9%-18.4%$931.51M$61.44M-4.49230Analyst ForecastHigh Trading VolumeSYRESpyre Therapeutics2.1508 of 5 stars$17.92-9.0%$54.83+206.0%-60.2%$921.59M$890,000.00-2.40100Positive NewsCOLLCollegium Pharmaceutical3.7881 of 5 stars$28.37-2.3%$43.60+53.7%-24.6%$914.87M$599.25M12.23210Insider TradeEOLSEvolus3.8254 of 5 stars$14.32-1.9%$23.67+65.3%-5.0%$906.57M$248.33M-15.73170Insider TradeZYMEZymeworks3.3487 of 5 stars$12.70-5.2%$19.17+51.0%+13.3%$874.54M$62.20M-8.46460Analyst ForecastInsider TradeAnalyst RevisionNews CoverageGap UpDAWNDay One Biopharmaceuticals2.5142 of 5 stars$8.26-8.9%$34.86+322.2%-43.6%$836.79M$131.16M-8.0260 Remove Ads Related Companies and Tools Related Companies NTLA Alternatives ELVN Alternatives ETNB Alternatives REPL Alternatives OCUL Alternatives SYRE Alternatives COLL Alternatives EOLS Alternatives ZYME Alternatives DAWN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NGNE) was last updated on 3/16/2025 by MarketBeat.com Staff From Our PartnersElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredForget Trump’s Tariffs, This March Event Is BiggerWhile everyone is distracted by Trump’s tariffs and a potential trade war… There’s something much bigger ha...Brownstone Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA new coin is elbowing its way to the top of the crypto worldWith Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredOur #1 Defense Stock for MarchChina just deepened its military alliance with America's enemies in the Middle East... By conducting joint ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
